RxDoctor Payments Data

Kevin Guillory, MD

Family Medicine · Opelousas, LANPI 1376740324

Payments from drug & device makers

$1,529in general payments, 2019–2025

Across 93 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$248
  • Lilly USA, LLC$210
  • AstraZeneca$202
  • Pfizer$141
  • AbbVie$97
  • Amgen$95
  • plus $537 from 15 others

What the payments were for

  • Food & beverage$1,529100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,529 in reported general payments places this provider in the 60th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$234,854
Medicare patients
358
Services billed
5,856

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate69$57,299
JardianceEmpagliflozin69$51,714
TrulicityDulaglutide28$30,512
OzempicSemaglutide25$28,090
FarxigaDapagliflozin Propanediol31$21,746
LinzessLinaclotide31$16,598
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$16,431
Breo ElliptaFluticasone/Vilanterol31$12,142
Tresiba Flextouch U-100Insulin Degludec16$11,214
TradjentaLinagliptin16$11,212
EliquisApixaban17$10,699
Janumet XrSitagliptin Phos/Metformin Hcl11$9,614
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$6,217
Pravastatin Sodium281$4,281
Rosuvastatin Calcium175$3,175

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet Xr$15$66,91380 claims
Boehringer IngelheimJardiance, Tradjenta$41$62,92585 claims
Lilly USA, LLCTrulicity$210$30,51228 claims
GSKTrelegy Ellipta, Breo Ellipta$67$28,57447 claims
Novo NordiskOzempic$248$28,09025 claims
AstraZenecaFarxiga$202$21,74631 claims
AbbVieLinzess$97$16,59831 claims
PfizerEliquis, Dilantin$141$13,16234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Opelousas

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →